Allergan Tops Earnings Estimates, Plans Buyback

The transcript discusses a company's financial performance, highlighting a $10 billion share buyback plan following a failed $160 billion deal with Pfizer. The company is selling its generics business to Teva for $40 billion and aims to stabilize shares. Despite a top line miss, the company maintains a $17 billion sales guidance, though analysts are cautious. The company plans to spend $4-5 billion in the coming months, with potential for future acquisitions despite existing debt. Analysts are reviewing ratings due to top line weakness, and the company's future prospects depend on meeting revenue targets.

What is the significance of the company's generics business in their overall strategy?

What are analysts saying about the company's sales guidance and its implications?